keyword
MENU ▼
Read by QxMD icon Read
search

Total PSA Free PSA

keyword
https://www.readbyqxmd.com/read/28811062/validation-of-the-prostate-health-index-in-a-predictive-model-of-prostate-cancer
#1
A Sanchís-Bonet, M Barrionuevo-González, A M Bajo-Chueca, L Pulido-Fonseca, L E Ortega-Polledo, J C Tamayo-Ruiz, M Sánchez-Chapado
OBJECTIVES: To validate and analyse the clinical usefulness of a predictive model of prostate cancer that incorporates the biomarker «[-2] pro prostate-specific antigen» using the prostate health index (PHI) in decision making for performing prostate biopsies. MATERIAL AND METHODS: We isolated serum from 197 men with an indication for prostate biopsy to determine the total prostate-specific antigen (tPSA), the free PSA fraction (fPSA) and the [-2] proPSA (p2PSA)...
August 12, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28804579/validity-of-prostate-health-index-and-percentage-of-2-pro-prostate-specific-antigen-as-novel-biomarkers-in-the-diagnosis-of-prostate-cancer-omani-tertiary-hospitals-experience
#2
Safana S Al Saidi, Nafila B Al Riyami, Mohammed S Al Marhoon, Mohammed S Al Saraf, Salim S Al Busaidi, Riad Bayoumi, Waad-Allah S Mula-Abed
OBJECTIVES: Prostate cancer is the leading cancer in older men. The Ministry of Health Oman Cancer Incidence Registry 2013 lists cancer of the prostate as the first most common cancer in males. Therefore, early detection is important and prostate-specific antigen (PSA) is widely used as an established laboratory test. However, despite its wide use, its value in screening, particularly in asymptomatic males, is controversial when considering the risks and benefits of early detection. METHODS: This prospective, observational study included 136 males (67...
July 2017: Oman Medical Journal
https://www.readbyqxmd.com/read/28801291/-value-of-pi-rads-v2-scores-combined-with-prostate-specific-antigen-in-diagnosis-of-peripheral-zone-prostate-cancer-a-logistic-regression-analysis
#3
Li-Zhi Lei, Yi-Kai Xu, Mei-Rong Hou, Meng-Qi He
OBJECTIVE: To assess the value of Prostate Imaging and Reporting and Data System: Version 2 (PI-RADS v2) combined with prostate specific antigen (PSA) in the diagnosis of peripheral zone (PZ) prostate cancer (PCa). METHODS: The preoperative magnetic resonance imaging and PSA data were ananlyzed for 69 patients with pathologically confirmed PCa and 109 non-PCa patients. PI-RADS v2 scores (1-5) was used to evaluate the risk of PZ PCa. The total PSA (tPSA) level, free to total PSA ratio (f/t PSA), PSA density (PSAD), PZ-PSAD and PI-RADS v2 scores were compared between the PCa and non-PCa patients...
August 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28791252/prostate-specific-antigen-5-years-following-stereotactic-body-radiation-therapy-for-low-and-intermediate-risk-prostate-cancer-an-ablative-procedure
#4
Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Brian T Collins, Simeng Suy, John H Lynch, Thomas Kole, Sean P Collins
BACKGROUND: Our previous work on early PSA kinetics following prostate stereotactic body radiation therapy (SBRT) demonstrated that an initial rapid and then slow PSA decline may result in very low PSA nadirs. This retrospective study sought to evaluate the PSA nadir 5 years following SBRT for low- and intermediate-risk prostate cancer (PCa). METHODS: 65 low- and 80 intermediate-risk PCa patients were treated definitively with SBRT to 35-37.5 Gy in 5 fractions at Georgetown University Hospital between January 2008 and October 2011...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28781111/creation-and-internal-validation-of-a-biopsy-avoidance-prediction-tool-to-aid-in-the-choice-of-diagnostic-approach-in-patients-with-prostate-cancer-suspicion
#5
Bimal Bhindi, Haiyan Jiang, Cedric Poyet, Thomas Hermanns, Robert J Hamilton, Kathy Li, Ants Toi, Antonio Finelli, Alexandre R Zlotta, Theodorus H van der Kwast, Andrew Evans, Neil E Fleshner, Girish S Kulkarni
INTRODUCTION: To reduce unnecessary prostate biopsies while using novel tests judiciously, we created a tool to predict the probability of clinically significant prostate cancer (CSPC) vs. low-risk prostate cancer or negative biopsy (i.e., when intervention is likely not needed) among men undergoing initial or repeat biopsy. METHODS: Separate models were created for men undergoing initial and repeat biopsy, identified from our institutional biopsy database and the placebo arm of the REDUCE trial, respectively, to predict the presence of CSPC (Gleason≥7 or>33% of cores involved)...
August 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28770408/phase-ii-study-of-radium-223-dichloride-in-japanese-patients-with-symptomatic-castration-resistant-prostate-cancer
#6
Nobuaki Matsubara, Satsohi Nagamori, Yoshiaki Wakumoto, Hirotsugu Uemura, Go Kimura, Akira Yokomizo, Hiroaki Kikukawa, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Hirokazu Tsutsui, Hiroji Uemura
BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. METHODS: In this open-label, multicenter, phase II study, patients with progressive, symptomatic CRPC and bone metastases were treated with radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles...
August 2, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28765515/the-prognostic-implication-of-intraductal-carcinoma-of-the-prostate-in-metastatic-castration-resistant-prostate-cancer-and-its-potential-predictive-value-in-those-treated-with-docetaxel-or-abiraterone-as-first-line-therapy
#7
Jinge Zhao, Pengfei Shen, Guangxi Sun, Ni Chen, Jiandong Liu, Xin Tang, Rui Huang, Diming Cai, Jing Gong, Xingming Zhang, Zhibin Chen, Xiang Li, Qiang Wei, Peng Zhang, Zhenhua Liu, Jiyan Liu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify its potential predictive role in making first-line treatment decisions for mCRPC. We retrospectively analyzed data of 131 mCRPC patients. IDC-P was diagnosed by re-biopsy at the time of mCRPC. Among total patients, 45 and 41 received abiraterone or docetaxel as first-line therapies, respectively...
July 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/28753827/the-cpc-risk-calculator-a-new-app-to-predict-prostate-specific-antigen-recurrence-during-follow-up-after-radical-prostatectomy
#8
Martin Andreas Røder, Kasper Drimer Berg, Mathias Dyrberg Loft, Frederik Birkebæk Thomsen, Michelle Ferrari, Sorel Kurbegovic, Helene Charlotte Rytgaard, Lisa Gruschy, Klaus Brasso, Thomas Alexander Gerds, Andreas Kjær, James D Brooks, Peter Iversen
BACKGROUND: It can be challenging to predict the risk of biochemical recurrence (BR) during follow-up after radical prostatectomy (RP) in men who have undetectable prostate-specific antigen (PSA), even years after surgery. OBJECTIVE: To establish and validate a contemporary nomogram that predicts the absolute risk of BR every year after RP in men with undetectable PSA while accounting for competing risks of death. DESIGN, SETTING, AND PARTICIPANTS: A total of 3746 patients from Rigshospitalet (Copenhagen, Denmark) and Stanford Urology (Stanford, CA, USA) who underwent RP between 1995 and 2013 were included...
December 9, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28752596/additional-value-of-the-ratio-of-serum-total-testosterone-to-total-prostate-specific-antigen-in-the-diagnosis-of-prostate-cancer-in-a-chinese-population
#9
L Xu, X Hu, Y Zhu, J Lu, Y Xu, G Wang, J Guo
We investigated whether serum testosterone and testosterone/prostate-specific antigen ratio (T/PSA) might be prostate cancer (PCa) biomarkers. We retrospectively reviewed 92 patients with benign prostatic hyperplasia (BPH) and 164 patients with PCa treated at Zhongshan Hospital, China (April 2012 to November 2013). The BPH and PCa groups had similar serum total testosterone (median, 15.8 versus 16.3 nmol/L).Compared with the BPH group, the PCa group had higher PSA (16.8 versus 5.1 ng/ml) and lower free/total PSA (9...
July 27, 2017: Andrologia
https://www.readbyqxmd.com/read/28735014/initial-clinical-experience-with-testosterone-undecanoate-therapy-aveed-%C3%A2-in-testosterone-deficient-men-in-the-united-states
#10
Abraham Morgentaler, Yonah Krakowsky, William Conners, Emily Davidson, Alex Rawji
OBJECTIVE: To report our initial experiences with TU 750mg in testosterone-deficient men. METHODS: All patients receiving TU 750mg at our center between July 1 2014 to August 1 2016 were identified. Clinical response was assessed via structured interviews and laboratory evaluations. Adverse events were documented, including increases in prostate specific antigen (PSA), hematocrit (Hct), and the development of post-injection cough. RESULTS: More than two injections were received by 147 men, with mean age 63...
July 19, 2017: Urology
https://www.readbyqxmd.com/read/28718092/no-significant-impact-of-prior-treatment-profile-with-docetaxel-on-the-efficacy-of-cabazitaxel-in-japanese-patients-with-metastatic-castration-resistant-prostate-cancer
#11
Hideaki Miyake, Takayuki Sugiyama, Ryota Aki, Yuto Matsushita, Keita Tamura, Daisuke Motoyama, Toshiki Ito, Atsushi Otsuka
The objective of this study was to retrospectively analyze the oncological outcomes of Japanese patients with metastatic castration-resistant prostate cancer (mCRPC) who received cabazitaxel. This study included a total of 63 consecutive Japanese mCRPC patients treated with cabazitaxel following the failure of docetaxel, and assessed the prognostic significance of cabazitaxel therapy in these patients focusing on the association of efficacies between two taxane agents. After treatment with cabazitaxel (median 5 cycles), prostate-specific antigen (PSA) decline was observed in 39 patients (61...
August 2017: Medical Oncology
https://www.readbyqxmd.com/read/28679370/assessment-of-free-hand-transperineal-targeted-prostate-biopsy-using-multiparametric-magnetic-resonance-imaging-transrectal-ultrasound-fusion-in-chinese-men-with-prior-negative-biopsy-and-elevated-prostate-specific-antigen
#12
Huibo Lian, Junlong Zhuang, Wei Wang, Bing Zhang, Jiong Shi, Danyan Li, Yao Fu, Xuping Jiang, Weimin Zhou, Hongqian Guo
BACKGROUND: To evaluate the role of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound (mpMRI-TRUS) fusion in Chinese men with repeated biopsy. METHODS: A total of 101 consecutive patients suspicious of prostate cancer (PCa) at the mpMRI scan and with prior negative biopsy and elevated PSA values were prospectively recruited at two urological centers. Suspicious areas on mpMRI were defined and graded using PI-RADS score...
July 5, 2017: BMC Urology
https://www.readbyqxmd.com/read/28667448/adjuvant-versus-salvage-radiotherapy-in-prostate-cancer-multi-institutional-retrospective-analysis-of-the-spanish-recap-database
#13
A Hervás, A Gómez-Caamaño, M Casaña, A Gómez-Iturriaga, J Pastor, J Jove, J L Mengual, C Gónzalez-San Segundo, J Muñoz
PURPOSE: To compare adjuvant radiotherapy (ART) to salvage radiotherapy (SRT) after radical prostatectomy (RP) in a cohort of prostate cancer (PCa) patients. The primary aim was to comparatively assess 2- and 5-year biochemical relapse-free survival (BRFS). A secondary aim was to identify predictors of survival. PATIENTS AND METHODS: Data were acquired from the RECAP database, a population-based prostate cancer registry in Spain. Inclusion criteria included RP (with or without lymphadenectomy) followed by ART or SRT...
June 30, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28646594/prevalence-and-prognosis-of-low-volume-oligorecurrent-hormone-sensitive-prostate-cancer-amenable-to-lesion-ablative-therapy
#14
Aurélie De Bruycker, Bieke Lambert, Tom Claeys, Louke Delrue, Chamberlain Mbah, Gert De Meerleer, Geert Villeirs, Filip De Vos, Kathia De Man, Karel Decaestecker, Valérie Fonteyne, Nicolaas Lumen, Filip Ameye, Ignace Billiet, Steven Joniau, Friedl Vanhaverbeke, Wim Duthoy, Piet Ost
OBJECTIVES: To describe the anatomical patterns of PCa recurrence following primary therapy and investigate if patients with low-volume disease have a better prognosis as compared to their counterparts. MATERIAL AND METHODS: Patients eligible for a F18-choline PET-CT were entered in a prospective cohort study. Eligible patients had an asymptomatic biochemical recurrence following primary PCa treatment and testosterone levels >50 ng/ml. The number of lesions were counted per scan...
June 24, 2017: BJU International
https://www.readbyqxmd.com/read/28643748/diagnostic-efficacy-of-free-prostate-specific-antigen-total-prostate-specific-antigen-ratio-for-the-diagnosis-of-prostate-cancer-in-low-concentration-%C3%A2-4-ng-ml-and-intermediate-levels-of-total-prostate-specific-antigen-4-01-10-0-ng-ml
#15
Selahattin Caliskan
AIM OF STUDY: Serum prostate-specific antigen (PSA) is a useful tumor biomarker for prostate cancer (PCa) diagnosis. In this study, I aimed to compare the free/total PSA (fPSA%) with PSA alone for their usefulness in diagnosis for PCa. METHODS: The patients who underwent prostate biopsy between January 2010 and January 2015 were evaluated retrospectively. Data were expressed as a mean + standard error and P < 0.05 as considered with statistical significance (Med Calc 14...
April 2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28636187/dual-labeled-chemiluminescence-enzyme-immunoassay-for-simultaneous-measurement-of-total-prostate-specific-antigen-tpsa-and-free-prostate-specific-antigen-fpsa
#16
Lixia Zhao, Dan Wang, Gen Shi, Ling Lin
The specificity for early diagnostic of prostate-specific antigen (PSA) is low because the current technology mostly allows the detection of only one biomarker at one time. In this work, a dual-labeled chemiluminescence enzyme immunoassay (CLEIA) for simultaneous measurement of total PSA (TPSA) and free PSA (FPSA) was proposed. Anti-PSA McAb (Mab1) was immobilized on a microplate as the solid phase, horseradish peroxidase (HRP)-labeled anti-TPSA monoclonal antibody (McAb2) and alkaline phosphatase (ALP)-labeled anti-FPSA McAb3 were used as detection antibodies...
June 21, 2017: Luminescence: the Journal of Biological and Chemical Luminescence
https://www.readbyqxmd.com/read/28624848/-177-lu-psma-617-radioligand-therapy-and-outcome-in-patients-with-metastasized-castration-resistant-prostate-cancer
#17
Axel Bräuer, Lena Sophie Grubert, Wolfgang Roll, Andres Jan Schrader, Michael Schäfers, Martin Bögemann, Kambiz Rahbar
PURPOSE: Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim of this study was to evaluate the overall survival (OS) and to identify parameters predicting outcome in mCRPC patients treated with (177)Lu-PSMA-617. METHODS: Between December 2014 and January 2017, 59 consecutive patients (median age 72 years; interquartile range, (IQR, 66-76 years) with mCRPC, who had been treated with at least one next-generation antihormonal drug as well as chemotherapy, were included in this study...
September 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28623636/eleven-year-management-of-prostate-cancer-patients-on-active-surveillance-what-have-we-learned
#18
Cristina Marenghi, Maria Francesca Alvisi, Federica Palorini, Barbara Avuzzi, Fabio Badenchini, Nice Bedini, Lara Bellardita, Davide Biasoni, Davide Bosetti, Alessandra Casale, Mario Catanzaro, Maurizio Colecchia, Letizia De Luca, Simona Donegani, Paola Dordoni, Rodolfo Lanocita, Massimo Maffezzini, Tiziana Magnani, Julia Menichetti, Antonella Messina, Sara Morlino, Biagio Paolini, Tiziana Rancati, Silvia Stagni, Antonio Tesone, Tullio Torelli, Edoardo Tulli Baldoin, Marta Vaiani, Sergio Villa, Silvia Villa, Nadia Zaffaroni, Nicola Nicolai, Roberto Salvioni, Riccardo Valdagni
PURPOSE: To evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate cancer (PCa) and to identify predictors of disease reclassification. METHODS: In 2005, we defined an institutional AS protocol (Sorveglianza Attiva Istituto Nazionale Tumori [SAINT]), and we joined the Prostate Cancer Research International: Active Surveillance (PRIAS) study in 2007. Eligibility criteria included clinical stage ≤T2a, initial prostate-specific antigen (PSA) <10 ng/mL, and Gleason Pattern Score (GPS) ≤3 + 3 (both protocols); ≤25% positive cores with a maximum core length containing cancer ≤50% (SAINT); and ≤2 positive cores and PSA density <0...
June 14, 2017: Tumori
https://www.readbyqxmd.com/read/28622770/intensity-modulated-radiation-therapy-from-70gy-to-80gy-in-prostate-cancer-six-year-outcomes-and-predictors-of-late-toxicity
#19
Maria Jolnerovski, Julia Salleron, Véronique Beckendorf, Didier Peiffert, Anne-Sophie Baumann, Valérie Bernier, Sandrine Huger, Vincent Marchesi, Ciprian Chira
OBJECTIVE: To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels. Identify predictors of radiation toxicity and report biochemical progression free survival (bPFS). METHODS: A total of 277 pts were treated with 70Gy (10.8%), 74Gy (63.9%) and 80 Gy (25.3%) using IMRT without pelvic irradiation were analyzed. Short or long-course androgen deprivation therapy (ADT) was allowed in 46...
June 16, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28613202/-comparison-of-two-on-line-risk-calculators-versus-the-detection-of-circulating-prostate-cells-for-the-detection-of-high-risk-prostate-cancer-at-first-biopsy
#20
COMPARATIVE STUDY
Nigel P Murray, Cynthia Fuentealba, Eduardo Reyes, Omar Jacob
OBJECTIVE: The limitations of total serum PSA values remains problematic; nomograms may improve the prediction of a positive prostate biopsy (PB). We compare in a prospective study of Chilean men with suspicion of prostate cancer due to an elevated total serum PSA and/or abnormal digital rectal examination, the use of two on-line nomograms with the detection of primary malignant circulating prostate cells (CPCs) to predict a positive PB for high risk prostate cancer. METHODS: Consecutive men with suspicion of prostate cancer underwent 12 core TRUS prostate biopsy...
June 2017: Archivos Españoles de Urología
keyword
keyword
68976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"